The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales

Eoghan M McCarthy¹, Emily Sutton², Stephanie Nesbit², Ben Parker^{1

3}, David Jayne⁴, Bridget Griffiths⁵, David A Isenberg⁶, Anisur Rahman⁶, Caroline Gordon^{7

8}, David P D'Cruz⁹, Benjamin Rhodes¹⁰, Peter Lanyon¹¹, Edward M Vital^{12

13}, Chee-Seng Yee¹⁴, Christopher J Edwards^{15

16}, Lee-Suan Teh¹⁷, Mohammed Akil¹⁸, Neil J McHugh^{19

20}, Asad Zoma²¹, Ian N Bruce^{1

2}; British Isles Lupus Assessment Group Biologics Register

Affiliations

¹ The Kellgren Centre for Rheumatology, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust.
² Arthritis Research UK Centre for Epidemiology.
³ Division of Musculoskeletal & Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester.
⁴ Department of Medicine, Addenbrooke's Hospital, Cambridge.
⁵ Department of Rheumatology, Freeman Hospital, Newcastle upon Tyne.
⁶ Division of Rheumatology, University College London, Rayne Institute, London.
⁷ Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham.
⁸ Rheumatology Department, City Hospital, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham.
⁹ Louise Coote Lupus Unit, Guys Hospital, London.
¹⁰ Rheumatology Department-University Hospitals Birmingham NHS Foundation Trust, Old Queen Elizabeth Hospital, Birmingham.
¹¹ Rheumatology Department, Nottingham University Hospitals NHS Trust, Nottingham.
¹² Leeds Institute for Rheumatic and Musculoskeletal Medicine, University of Leeds.
¹³ NIHR Leeds Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds.
¹⁴ Department of Rheumatology, Doncaster and Bassetlaw Hospitals NHS Foundation Trust, Doncaster.
¹⁵ Musculoskeletal Research Unit, NIHR Wellcome Trust Clinical Research facility, The University of Southampton.
¹⁶ University Hospital Southampton NHS Foundation Trust, Southampton, UK.
¹⁷ Department of Rheumatology, Royal Blackburn Hospital, Blackburn.
¹⁸ Rheumatology Department, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield.
¹⁹ Department of Rheumatology, Royal National Hospital for Rheumatic Diseases and Royal United Hospitals Bath NHS Foundation Trust.
²⁰ Department of Pharmacy and Pharmacology, University of Bath, Bath.
²¹ Rheumatology Department, Hairmyres Hospital, Lanarkshire, UK.

PMID: 28431104
PMCID: PMC5850864
DOI: 10.1093/rheumatology/kex044

The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales

Eoghan M McCarthy et al. Rheumatology (Oxford). 2017.

. 2017 Jun 1;56(6):1041-1043.

doi: 10.1093/rheumatology/kex044.

Authors

Affiliations

¹ The Kellgren Centre for Rheumatology, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust.
² Arthritis Research UK Centre for Epidemiology.
³ Division of Musculoskeletal & Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester.
⁴ Department of Medicine, Addenbrooke's Hospital, Cambridge.
⁵ Department of Rheumatology, Freeman Hospital, Newcastle upon Tyne.
⁶ Division of Rheumatology, University College London, Rayne Institute, London.
⁷ Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham.
⁸ Rheumatology Department, City Hospital, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham.
⁹ Louise Coote Lupus Unit, Guys Hospital, London.
¹⁰ Rheumatology Department-University Hospitals Birmingham NHS Foundation Trust, Old Queen Elizabeth Hospital, Birmingham.
¹¹ Rheumatology Department, Nottingham University Hospitals NHS Trust, Nottingham.
¹² Leeds Institute for Rheumatic and Musculoskeletal Medicine, University of Leeds.
¹³ NIHR Leeds Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds.
¹⁴ Department of Rheumatology, Doncaster and Bassetlaw Hospitals NHS Foundation Trust, Doncaster.
¹⁵ Musculoskeletal Research Unit, NIHR Wellcome Trust Clinical Research facility, The University of Southampton.
¹⁶ University Hospital Southampton NHS Foundation Trust, Southampton, UK.
¹⁷ Department of Rheumatology, Royal Blackburn Hospital, Blackburn.
¹⁸ Rheumatology Department, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield.
¹⁹ Department of Rheumatology, Royal National Hospital for Rheumatic Diseases and Royal United Hospitals Bath NHS Foundation Trust.
²⁰ Department of Pharmacy and Pharmacology, University of Bath, Bath.
²¹ Rheumatology Department, Hairmyres Hospital, Lanarkshire, UK.

PMID: 28431104
PMCID: PMC5850864
DOI: 10.1093/rheumatology/kex044

Erratum in

The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales.
McCarthy EM, Sutton E, Nesbit S, Parker B, Jayne D, Griffiths B, Isenberg DA, Rahman A, Gordon C, D'Cruz DP, Rhodes B, Lanyon P, Vital EM, Yee CS, Edwards CJ, Teh LS, Akil M, McHugh NJ, Zoma A, Bruce IN; British Isles Lupus Assessment Group Biologics Register. McCarthy EM, et al. Rheumatology (Oxford). 2017 Jun 1;56(6):1049. doi: 10.1093/rheumatology/kex218. Rheumatology (Oxford). 2017. PMID: 28549192 Free PMC article. No abstract available.

No abstract available

PubMed Disclaimer

Figures

F<sc>ig</sc>. 1 — **Fig. 1**
BILAG-2004 organ systems with active disease in SLE patients eligible for belimumab Number of individual patients scoring either an A or B on BILAG-2004 scoring system across the systems assessed.

See this image and copyright information in PMC

References

1. Navarra SV, Guzmán RM, Gallacher AE. et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721–31. - PubMed
1. Furie R, Petri M, Zamani O. et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918–30. - PMC - PubMed
1. van Vollenhoven RF, Petri MA, Cervera R. et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 2012;71:1343–9. - PMC - PubMed
1. http://www.ema.europa.eu/ema/index.jsp%3Fcurl=pages/medicines/human/medi... (August 2011, date last accessed).
1. National Institute for Health and Care Excellence. Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus. Vol. 2016; 2016. https://www.nice.org.uk/guidance/ta397.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales

Affiliations

The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales

Authors

Affiliations

Erratum in

Figures

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical